Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) Non Operating Investment Income (2019 - 2023)

Benitec Biopharma (BNTC) has disclosed Non Operating Investment Income for 5 consecutive years, with -$1000.0 as the latest value for Q4 2023.

  • Quarterly Non Operating Investment Income rose 66.67% to -$1000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$1000.0 through Dec 2024, up 75.0% year-over-year, with the annual reading at -$1000.0 for FY2024, 66.67% up from the prior year.
  • Non Operating Investment Income hit -$1000.0 in Q4 2023 for Benitec Biopharma, down from $1000.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $19000.0 in Q2 2021 to a low of -$23000.0 in Q4 2021.
  • Historically, Non Operating Investment Income has averaged $71.43 across 5 years, with a median of -$1000.0 in 2019.
  • Biggest five-year swings in Non Operating Investment Income: crashed 2200.0% in 2021 and later skyrocketed 200.0% in 2023.
  • Year by year, Non Operating Investment Income stood at -$1000.0 in 2019, then changed by 0.0% to -$1000.0 in 2020, then plummeted by 2200.0% to -$23000.0 in 2021, then soared by 86.96% to -$3000.0 in 2022, then soared by 66.67% to -$1000.0 in 2023.
  • Business Quant data shows Non Operating Investment Income for BNTC at -$1000.0 in Q4 2023, $1000.0 in Q2 2023, and -$4000.0 in Q1 2023.